Surgical robotics company CMR Surgical – the global surgical robotics company – announced the closing of a financing round of over $200 million through a combination of equity and debt capital to support the company’s ambitious growth plans. The funding, which was supported by all the company’s existing major investors, includes a new debt investment from Trinity Capital.
CMR will use the funding to accelerate the commercial expansion of the Versius Surgical Robotic System to more hospitals worldwide, with a significant focus on launching Versius in the US. The goal is to continue advancing surgical robotics innovation and product development.
Versius, the second most utilised soft tissue surgical robot globally, has been used to complete more than 30,000 surgical cases globally in over 30 countries. The increasing adoption of surgical robotics has fueled the increase in Versius installations.
CMR is actively expanding its clinical footprint with two ongoing clinical trials: a pioneering paediatrics study, the world’s first multicenter prospective trial on the use of Versius in paediatric surgery, and a transoral robotic surgery (TORS) trial, which further demonstrates Versius’s versatility and capability in new surgical applications.
Versius resets expectations of robotic surgery. It fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). Versius’ small and modular design allows the surgeon to use only the arms needed for a procedure.
Biomimicking the human arm, Versius provides surgeons the choice of optimised port placement alongside the dexterity and accuracy of small, fully-wristed instruments. And with 3D HD vision, easy-to-adapt instrument control, and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue. It allows for clear communication with the surgical team. By thinking laparoscopically and operating robotically with Versius, patients, surgeons, and healthcare professionals can all benefit from the value of robotic MAS.
Versius also captures meaningful data with its broader digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer, and CMR clinical registry, Versius features many insights that ultimately improve surgical care.
Armentum Partners acted as CMR’s financial advisor on the debt financing.
KEY QUOTES:
“CMR is a competitive, well-established company with a transformative product providing clear clinical value. We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets. I would like to give thanks to our CFO, Andre Nel, and the team for securing this financing to provide the foundation for realising our strategic vision of making robotic assisted surgery accessible to all patients who need it whilst accelerating future product development. I would also like to thank our investors for their continued support and look forward to delivering sustainable growth and life-changing solutions to the global healthcare community.“
- Massimiliano Colella, Chief Executive Officer at CMR Surgical
“Trinity Capital is excited to partner with CMR Surgical at this important juncture. CMR has established itself as a trailblazer in surgical robotics, with Versius already proving its value to surgeons and patients worldwide. We are confident in CMR’s vision and leadership, and our investment reflects our belief that Versius will continue to drive a new era in minimally invasive surgery. We look forward to supporting CMR as it continues to scale and transform surgical care on a global level.”
- Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital
“The recent funding is a strong vote of confidence in the future of surgical robotics and in CMR as a leader within this space. This investment is a significant endorsement of Max and his leadership team and provides them with the resources needed to execute on their strategic plan. We are pleased to have the continued support of our investors as we embark on this next phase of growth.”
- Dan Moore, Non-Executive Chairman at CMR Surgical
“This successful funding round of more than $200M is a clear vote of confidence in the company, the potential of surgical robotics, and in the UK’s life science ecosystem, which continues to produce innovative companies at an impressive rate. “We will continue to back world-class innovation and companies like CMR Surgical as they realise their global ambitions and support the creation of high-quality jobs in the UK.”
- UK Science Minister and Oxford Cambridge Corridor Champion Lord Vallance
